27
Oct
A fixed dose combination (FDC) of Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin (first-line medication for the treatment of type 2diabetes) has been launched by Glenmark Pharmaceuticals Limited (Glenmark). Glenmark has launched the same under two brand names Remo MV and Remozen MV. This fixed drug combination is indicated for the management of Type 2 diabetes. The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily. Glenmark is the first company in the…
